MedTrace Logo

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00222170 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-05-08

No results posted yet for this study

Summary

The purpose of this study is to determine the production of mucin in GERD/RE subjects before and after 8 weeks of treatment with rabeprazole.

Conditions

  • Esophageal Reflux

Interventions

DRUG

Rabeprazole

Sponsors & Collaborators

  • PriCara, Unit of Ortho-McNeil, Inc.

    collaborator INDUSTRY

  • Eisai Inc.

    collaborator INDUSTRY

  • University of Kansas

    lead OTHER

Principal Investigators

  • Jerzy Sarosiek, PhD · University of Kansas Medical Center

  • Mojtaba S. Olyaee, MD · University of Kansas Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222170 on ClinicalTrials.gov